<DOC>
	<DOCNO>NCT00004137</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus filgrastim treating patient previously untreated extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>S9914 : Combination Chemotherapy Plus Filgrastim Untreated Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess survival response rate patient previously untreated extensive stage small cell lung cancer treat paclitaxel , carboplatin , topotecan , filgrastim ( G-CSF ) . II . Determine side effect toxicity regimen patient . OUTLINE : Patients receive topotecan IV 30 minute day 1-4 paclitaxel IV 1 hour follow carboplatin IV 1 hour prior topotecan day 4 . Patients receive filgrastim ( G-CSF ) subcutaneously daily begin day 5 continue blood count recover . G-CSF must discontinue least 24 hour prior begin subsequent course chemotherapy . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients follow every 6 month 3 year . PROJECTED ACCRUAL : A total 75 patient accrue study 18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven , previously untreated extensive stage small cell lung cancer ( SCLC ) Brain metastasis allow : Asymptomatic OR Previously treat radiotherapy and/or surgery Measurable evaluable disease outside area prior surgical resection new lesion must present PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm3 WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Renal : Creatinine great ULN Creatinine clearance least 50 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : No prior systemic biologic therapy SCLC Chemotherapy : No prior systemic chemotherapy SCLC Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy SCLC Surgery : See Disease Characteristics At least 2 week since prior thoracic major surgery recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>